Evidence map›Paper›PMID 26953561›Full record

ReviewCurrent opinion in genetics & development2016

Mitochondria in pluripotent stem cells: stemness regulators and disease targets.

Clifford Dl Folmes, Hong Ma, Shoukhrat Mitalipov, Andre Terzic

Abstract readReview
In one paragraph

Review in Current opinion in genetics & development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Metabolic control of induced pluripotency.Frontiers in cell and developmental biology · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Energy Metabolism Regulates Stem Cell Pluripotency.Frontiers in cell and developmental biology · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Clifford Dl FolmesCenter for Regenerative Medicine, Mayo Clinic, Rochester, MN 55905, USA; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Hong MaCenter for Embryonic Cell and Gene Therapy, Oregon Health & Science University, Portland, OR 97239, USA; Division of Reproductive & Developmental Sciences, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Shoukhrat MitalipovCenter for Embryonic Cell and Gene Therapy, Oregon Health & Science University, Portland, OR 97239, USA; Division of Reproductive & Developmental Sciences, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. Electronic address: mitalipo@oshu.edu.
Andre TerzicCenter for Regenerative Medicine, Mayo Clinic, Rochester, MN 55905, USA; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: terzic.andre@mayo.edu.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Histocompatible Primate Embryonic Stem CellsR01HD057121 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MITALIPOV, SHOUKHRAT · 2009 to 2013
$3.4M
Mitochondrial Gene TherapyR01HD063276 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MITALIPOV, SHOUKHRAT · 2010 to 2014
$3.0M
Altered Nuclear TransferR01HD059946 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MITALIPOV, SHOUKHRAT · 2010 to 2014
$2.7M
Metabolic reprogramming in pluripotent induction and cardiac lineage specificatioK99HL121079 · NHLBI · MAYO CLINIC ROCHESTER · PI FOLMES, CLIFFORD D · 2014 to 2015
$279k
NHLBI NIH HHS K99 HL121079NICHD NIH HHS R01 HD057121NICHD NIH HHS R01 HD059946NICHD NIH HHS R01 HD063276NIH HHS P51 OD011092
6 · The paper itself

Abstract

Beyond their canonical role in efficient ATP production through oxidative metabolism, mitochondria are increasingly recognized as critical in defining stem cell function and fate. Implicating a fundamental interplay within the epigenetics of eukaryotic cell systems, the integrity of mitochondria is found vital across the developmental/differentiation spectrum from securing pluripotency maintenance to informing organotypic decisions. This overview will discuss recent progress on examining the plasticity of mitochondria in enabling the execution of programming and reprogramming regimens, as well as the application of nuclear reprogramming and somatic cell nuclear transfer as rescue techniques to generate genetically and functionally corrected pluripotent stem cells from patients with mitochondrial DNA-based disease.

Indexed as

Pluripotent Stem CellsCell PlasticityCellular ReprogrammingEpigenomicsHumansMitochondriaMitochondrial DiseasesNuclear Transfer Techniques

Identifiers

PMID26953561
PMCPMC5011451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.